» Articles » PMID: 38001645

Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001645
Authors
Affiliations
Soon will be listed here.
Abstract

A simple way to understand the immune system is to separate the self from non-self. If it is self, the immune system tolerates and spares. If it is non-self, the immune system attacks and destroys. Consequently, if cancer has a stem cell origin and is a stem cell disease, we have a serious problem and a major dilemma with immunotherapy. Because many refractory cancers are more self than non-self, immunotherapy may become an uphill battle and pyrrhic victory in cancer care. In this article, we elucidate cancer immunity. We demonstrate for whom, with what, as well as when and how to apply immunotherapy in cancer care. We illustrate that a stem cell theory of cancer affects our perspectives and narratives of cancer. Without a pertinent theory about cancer's origin and nature, we may unwittingly perform misdirected cancer research and prescribe misguided cancer treatments. In the ongoing saga of immunotherapy, we are at a critical juncture. Because of the allure and promises of immunotherapy, we will be treating more patients not immediately threatened by their cancer. They may have more to lose than to gain, if we have a misconception and if we are on a wrong mission with immunotherapy. According to the stem cell theory of cancer, we should be careful with immunotherapy. When we do not know or realize that cancer originates from a stem cell and has stem-ness capabilities, we may cause more harm than good in some patients and fail to separate the truth from the myth about immunotherapy in cancer care.

Citing Articles

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.

Tu S, Trikannad A, Vellanki S, Hussain M, Malik N, Singh S Cancers (Basel). 2024; 16(6).

PMID: 38539487 PMC: 10969562. DOI: 10.3390/cancers16061151.


Links WNT and Retinoic Acid Signaling: A Target to Differentiate ALDH+ Stem Cells in -Mutant CRC.

Facey C, Hunsu V, Zhang C, Osmond B, Opdenaker L, Boman B Cancers (Basel). 2024; 16(2).

PMID: 38254755 PMC: 10813786. DOI: 10.3390/cancers16020264.

References
1.
Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov A, Gorelov S . An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008; 372(9633):145-154. DOI: 10.1016/S0140-6736(08)60697-2. View

2.
Ribas A, Kefford R, Marshall M, Punt C, Haanen J, Marmol M . Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31(5):616-22. PMC: 4878048. DOI: 10.1200/JCO.2012.44.6112. View

3.
Gu Y, Xue Q, Chen Y, Yu G, Qing M, Shen Y . Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Hum Immunol. 2012; 74(3):267-76. DOI: 10.1016/j.humimm.2012.12.011. View

4.
Rini B, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S . IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016; 17(11):1599-1611. DOI: 10.1016/S1470-2045(16)30408-9. View

5.
Umbreit E, Siddiqui B, Hwang M, Joon A, Maity T, Westerman M . Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020; 12(12). PMC: 7764868. DOI: 10.3390/cancers12123755. View